Amylin Analog – BiotechReality – Information Intelligence System for Biopharma

Quick Summary Positive Phase 1 MAD Results: Statistically significant body weight reductions vs. placebo across multiple dose cohorts, validating the amylin receptor pathway. Differentiated Tolerability Profile: Lower nausea burden vs. GLP-1 comparators addresses the #1 adherence barrier in the obesity drug class. Phase 2 Advancement Planned: AbbVie intends to move into a Phase 2 dose-ranging study, a key pipeline milestone for its cardiometabolic franchise. AbbVie (NYSE: ABBV) announced on March 9, 2026, positive topline results from a Phase 1 multiple ascending dose (MAD) study evaluating ABBV-295 the company's investigational long-acting amylin analog in adults with overweight or obesity. The results confirm that ABBV-295 achieves statistically significant reductions in body weight compared to placebo, while demonstrating a differentiated and favorable tolerability profile. This combination is particularly compelling in a competitive obesity therapeutics market increasingly dominated by GLP-1 receptor agonists, where gastrointestinal side effects remain the primary driver of patient discontinuation. The announcement marks a significant milestone for AbbVie's emerging cardiometabolic pipeline, positioning ABBV-295 as a potential best-in-class or first-in-class asset leveraging the amylin pathway a mechanism of action entirely distinct from the GLP-1/GIP pathways exploited by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Background: The Amylin Pathway Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It plays a crucial, multifaceted role in regulating postprandial physiology and has long been recognized as a pharmacologically rich target for metabolic disease. Key physiological roles relevant to ABBV-295: Central satiety signaling via area postrema and nucleus of the solitary tract is independent of GLP-1 pathways. Appetite suppression reduces meal-initiated food intake through distinct hypothalamic circuits. Gastric emptying modulation to dampen postprandial glucose excursions. Glucagon suppression during meals contributes to glycemic control. Synergy with GLP-1 agonists when co-administered, suggesting a compelling combination therapy potential. Despite this validated biology, the development of amylin-based therapies has historically been hampered by aggregation propensity, a formulation challenge that limited the original amylin analog pramlintide (Symlin) to short-acting, multiple-daily-injection regimens with modest efficacy. ABBV-295 represents a next-generation long-acting amylin analog engineered to overcome these barriers through novel molecular stabilization, enabling once-weekly subcutaneous administration. Read More: AbbVie Reports Breakthrough Results for RINVOQ® (Upadacitinib) in Alopecia Areata Treatment Phase 1 MAD Study: Design The Phase 1 MAD study was a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of ABBV-295 in adult participants with overweight or obesity (BMI ≥27 kg/m²). The MAD design involving repeated doses at sequentially higher levels with safety review between cohorts is the gold-standard methodology for establishing a safe and efficacious dose range prior to Phase 2 dose-selection trials. It informs maximum tolerated dose (MTD), no-observed-adverse-effect level (NOAEL), and optimal pharmacological dose (OPD) determinations. Study objectives: Primary: Safety and tolerability of ABBV-295 across multiple ascending dose levels Secondary: PK/PD characterization following once-weekly subcutaneous dosing Exploratory: Effect of ABBV-295 on body weight and key cardiometabolic biomarkers Clinical Data Summary ParameterFindingClinical SignificanceStudy DesignPhase 1, Randomized, Double-blind, Placebo-controlled MADGold-standard early-phase design; minimizes biasMoleculeABBV-295 — long-acting amylin analog (weekly SC injection)Once-weekly dosing improves adherence vs. daily injectablesPopulationAdults with overweight/obesity (BMI ≥27 kg/m²)Broad phenotype; real-world commercial relevancePrimary EndpointSafety, tolerability & PK/PD profileFoundation for Phase 2 dose selectionWeight ReductionStatistically Significant vs. placebo across dose cohortsValidates amylin pathway as viable obesity target in humansTolerabilityFavorable; GI AEs mild-to-moderate, transientDifferentiated from GLP-1 receptor agonist class profileNauseaLower relative nausea vs. GLP-1 comparators (historical)Addresses #1 adherence barrier in obesity drug classSAEsNone Attributed to ABBV-295Supports dose escalation and Phase 2 entryBiomarkersImprovements in fasting glucose & lipid parameters (exploratory)Signals cardiometabolic benefit beyond weight reductionDosingOnce-Weekly SCCompetitive with semaglutide and tirzepatide convenienceNext StepsPhase 2 dose-ranging study plannedAccelerated development timeline supported by robust Phase 1 package Key Efficacy Findings The centerpiece of AbbVie's announcement was the achievement of statistically significant body weight reduction versus placebo across multiple dose cohorts, a result not universally expected from a Phase 1 MAD study, which is primarily powered for safety rather than efficacy. This early efficacy signal meaningfully de-risks the clinical development program and provides confidence in the biological activity of ABBV-295 in humans. The dose-dependent relationship between ABBV-295 exposure and weight loss suggests a robust pharmacodynamic effect consistent with amylin-mediated satiety mechanisms. Cardiometabolic biomarker improvements: Beyond weight reduction, exploratory analyses pointed to improvements in fasting glucose and lipid parameters indicating potential cardiometabolic benefits that could strengthen labeling and commercial positioning if confirmed in Phase 2/3 trials. PK/PD profile ABBV-295 demonstrated a pharmacokinetic profile consistent with once-weekly dosing, with an exposure-response relationship that supports dose selection for Phase 2 development. The long-acting formulation technology appears to have successfully addressed the aggregation challenges that limited prior amylin analogs. Read More: New anti-obesity drugs reduces weight-loss surgery numbers Tolerability: The Key Differentiator In the obesity therapeutics market, tolerability, particularly gastrointestinal tolerability, is increasingly recognized as a critical driver of real-world adherence and commercial success. GLP-1 receptor agonists, while highly effective, carry high rates of nausea, vomiting, and constipation that limit dose escalation and drive discontinuation in a meaningful proportion of patients. ABBV-295's Phase 1 MAD data revealed a tolerability profile that may represent a genuine clinical and commercial differentiator: GI adverse events were generally mild-to-moderate in severity and transient in nature. Nausea rates appeared lower relative to historical GLP-1 comparators at equivalent efficacy dose ranges. No serious adverse events attributed to ABBV-295 were reported in the topline data. The safety profile was consistent across dose cohorts, supporting dose escalation into Phase 2. Development Pathway Following the positive Phase 1 MAD results, AbbVie has indicated its intention to advance ABBV-295 into a Phase 2 dose-ranging study. The Phase 2 program will be designed to: Confirm dose-response relationships for weight loss and metabolic endpoints in a larger, more representative population Evaluate long-term safety and tolerability over extended treatment duration (typically 16–52 weeks) Explore ABBV-295 in combination with GLP-1 receptor agonists to assess additive or synergistic efficacy Identify target patient populations, particularly those intolerant to or inadequately responding to existing GLP-1 therapies Subject to Phase 2 results, the program could advance to pivotal Phase 3 trials targeting regulatory submission by the late 2020s. The strong Phase 1 data package supports an expedited development timeline, and AbbVie's commercial infrastructure, built over decades of blockbuster drug launches, provides a meaningful go-to-market advantage should ABBV-295 reach approval. AbbVie Last Modified:

Tag: Amylin Analog

AbbVie’s ABBV-295 Long-Acting Amylin Analog Delivers Positive Phase 1 MAD Results

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment